HAIKOU, China, May 17, 2017 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma," the "Company" or "We"), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced its wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., participated in PharmChina and API (Active Pharmaceutical Ingredient) China.
The 77th PHARMCHINA, and the 78th API China takes place on May 15 - 18, 2017, National Exhibition and Convention Center, Shanghai, China. With a long history and great influence in the APAC region, this event involves pharmaceutical research and development, production, sales and marketing; is one of the best platforms to understand the pulse and latest trends of this industry. There has been over 120,000 visitors mainly from pharmaceutical manufacturers, distributors/agents, and pharmacy chains.
Hainan Helpson Medical & Biotechnology Co., Ltd., is showing around 20 products for the treatment of anti-infection & respiratory system diseases, central nervous system diseases, digestive diseases, and other diseases in this event; and is communicating with a wide range of existing and potential distributors and API suppliers.
"To participate in this event is to further improve our market share, strengthen cooperation with upstream and downstream companies, in-depth understand frontier information, and explore global layout," China Pharma's President & CEO, Ms. Li Zhilin. "We have been actively talking to international API exhibitors to leverage any win-win cooperation models in the current pharmaceutical policy environment in China. We will continue enhancing our fundamentals in operating level to support and promote our long-term growth."
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.
Safe Harbor Statement
Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations except as required by applicable law or regulation.
Contact:
China Pharma Holdings, Inc.
Ms. Diana Na Huang
Phone: +86-898-6681-1730 (China)
Email: hps@chinapharmaholdings.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-pharma-holdings-incs-wholly-owned-subsidiary-participated-in-pharmchinaapi-china-conferences-300459156.html
